The Korea Food & Drug Administration approved the safety and function of tagatose for controlling postprandial blood glucose level. Tagatose reduces blood glucose level in the liver by promoting glucokinase activity which promotes transfer of glucose to glycogen. It also inhibits digestive enzymes and degradation of carbohydrates in small intestine which result in inhibition of carbohydrate absorption in the body. Clinical studies have shown that tagatose significantly reduces blood glucose levels among healthy, prediabetic, impaired fasting glucose, and impaired glucose tolerance subjects. Antihyperglycemic function is important for those with both type 1 diabetes mellitus and type 2 diabetes mellitus especially because diabetes is continuously growing and spreading to the younger generation. US$92 billion was spent for diabetes medication in 2008 in the US, and US$50 billion is paid in China per year.